Furthermore, downregulation of ZCCHC4 increases sensitivity to cisplatin treatment, promotes apoptosis, and inhibits proliferation of esophageal cancer cells, potentially through the ROS/c-myc axis. Here, MYC is linked to esophageal cancer.